SHANGHAI – One-year-old Terns Pharmaceuticals will seed its pipeline with three candidates for nonalcoholic steatohepatitis (NASH), having acquired global development and commercialization rights from Eli Lilly and Co., of Indianapolis. Terns intends to take a China-first strategy for the development and registration of these candidates for liver disease while remaining open to global opportunities. Read More
HONG KONG – The Trump administration has proposed placing a 25 percent tariff on more than 1,300 imported goods from China, such as biotech materials and medical devices, a move some say could eventually hurt U.S. drugmakers. Read More
PERTH, Australia – Sydney-based Kazia Therapeutics Ltd. has begun a U.S. phase II trial in glioblastoma with lead candidate GDC-0084, in-licensed from Roche Holding AG unit Genentech. Read More
HONG KONG – A neural plasticity enhancer, edonerpic maleate, could be the first clinically effective compound for accelerating rehabilitation after brain damage, potentially revolutionizing the future management of stroke patients, according to the results of a new Japanese study reported in the April 6, 2018, edition of Science. Read More
PERTH, Australia – A new class of synthetic antibiotics with broad-spectrum activity is being developed by Sydney-based Recce Pharmaceuticals Ltd. that could solve the problem of antibiotic resistance. Read More
The Cancer Genome Atlas (TCGA), a comprehensive program that used sequencing to understand the genomic landscapes of 33 different tumor types, published its results last week in almost 30 papers in a half dozen different Cell Press journals. Read More
HONG KONG – China's Zai Lab Ltd. has returned the exclusive sales license of lung cancer drug Olita Tab (olmutinib) to its developer, South Korea's Hanmi Pharmaceutical Co. Ltd., a move Zai attributed to reprioritization, though Olita Tab has run into problems in clinical studies. Read More
